Willow Biosciences Inc.
WLLW.TO
TSX
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 1.34M | 1.25M | 749.80K | 37.80K | 65.40K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.34M | 1.25M | 749.80K | 37.80K | 65.40K |
| Cost of Revenue | -1.76M | 1.04M | 898.90K | 823.30K | 866.60K |
| Gross Profit | 4.45M | 207.50K | -149.10K | -785.50K | -801.20K |
| SG&A Expenses | 620.80K | 731.00K | 649.70K | 775.10K | 932.00K |
| Depreciation & Amortization | 262.20K | 230.20K | 258.00K | 261.10K | 277.10K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.81M | 2.00M | 1.81M | 1.86M | 2.08M |
| Operating Income | -465.10K | -753.70K | -1.06M | -1.82M | -2.01M |
| Income Before Tax | -894.40K | -792.60K | -1.09M | -1.75M | -1.80M |
| Income Tax Expenses | -252.90K | 121.00K | 138.90K | 1.50K | -18.40K |
| Earnings from Continuing Operations | -641.50K | -913.50K | -1.23M | -1.75M | -1.78M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -641.50K | -913.50K | -1.23M | -1.75M | -1.78M |
| EBIT | -465.10K | -753.70K | -1.06M | -1.82M | -2.01M |
| EBITDA | -205.70K | -649.60K | -925.90K | -1.69M | -1.86M |
| EPS Basic | 0.00 | -0.01 | -0.01 | -0.01 | -0.01 |
| Normalized Basic EPS | 0.00 | 0.00 | -0.01 | -0.01 | -0.01 |
| EPS Diluted | 0.00 | -0.01 | -0.01 | -0.01 | -0.01 |
| Normalized Diluted EPS | 0.00 | 0.00 | -0.01 | -0.01 | -0.01 |
| Average Basic Shares Outstanding | 142.33M | 141.14M | 127.25M | 125.44M | 124.29M |
| Average Diluted Shares Outstanding | 142.33M | 141.14M | 127.25M | 125.44M | 124.29M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
